<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9860">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688696</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00124</org_study_id>
    <nct_id>NCT05688696</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IIb, randomized, double-blind, placebo-controlled, multicenter study to&#xD;
      evaluate the efficacy and safety of orelabrutinib in adult subjects with SLE who are&#xD;
      receiving standard of care (SOC) therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2023</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SLE Responder Index (SRI) - 4 response rate</measure>
    <time_frame>Week 48</time_frame>
    <description>SRI-4 response is defined as: 1)≥4 point reduction from baseline in SLE disease activity index-2000 (SLEDAI-2K) score; 2) no worsening (increase of &lt;0.3 points from baseline) in Physician's Global Assessment (PGA); 3) no new A organ domain score or no more than 1 new B organ domain scores compared with baseline in British Isles Lupus Assessment Group (BILAG)-2004.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SLE Responder Index (SRI) - 6 response rate</measure>
    <time_frame>Week 48</time_frame>
    <description>SRI-6 response is defined as: 1)≥6 point reduction from baseline in SLE disease activity index-2000 (SLEDAI-2K) score; 2) no worsening (increase of &lt;0.3 points from baseline) in Physician's Global Assessment (PGA); 3) no new A organ domain score or no more than 1 new B organ domain scores compared with baseline in British Isles Lupus Assessment Group (BILAG)-2004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rate</measure>
    <time_frame>Week 48</time_frame>
    <description>BICLA response is defined as: 1) In BILAG-2004, reduction of all baseline A to B/C/D and baseline B to C/D, and no worsening in other organ systems (as defined by no new A organ domain score or no more than 1 new B organ domain scores); 2) No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of &gt;0 points in SLEDAI-2K; 3) No worsening (increase of &lt;0.3 points from baseline) in PGA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1st flare</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects whose average prednisone dose has been reduced by≥25% from baseline to ≤7.5 mg/day</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the levels of complement C3, complement C4, and anti-dsDNA antibody</measure>
    <time_frame>Week 48</time_frame>
    <description>Adopt the unified unit standard of central laboratory testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events, Treatment Related Adverse Events, Treatment Emergent Serious Adverse Events, Treatment Related Serious Adverse Events.</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the 36-Item Short Form Health Survey (SF-36) scores (The SF-36 consists of eight domains. Each domain score ranges from 0-100. The higher the score, the better the health. )</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Systemic Lupus Erythematosus, SLE</condition>
  <arm_group>
    <arm_group_label>Orelabrutinib Lower Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orelabrutinib Higher Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib (Low Dose)</intervention_name>
    <description>Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy</description>
    <arm_group_label>Orelabrutinib Lower Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib (High Dose)</intervention_name>
    <description>Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy</description>
    <arm_group_label>Orelabrutinib Higher Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib Placebo</intervention_name>
    <description>Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. have had a detailed understanding of the nature, significance, potential benefits,&#xD;
             potential risks, and procedures of the study, and voluntarily signed a written&#xD;
             Informed Consent Form (ICF).&#xD;
&#xD;
          2. Males or females aged≥18 and ≤75 years.&#xD;
&#xD;
          3. Have a clinical diagnosis of SLE 6 months prior to signing the ICF, meeting at least 4&#xD;
             of the 11 American College of Rheumatology (ACR) classification criteria for SLE.&#xD;
&#xD;
          4. SLEDAI-2K≥8 at screening.&#xD;
&#xD;
          5. Are on a stable SLE SOC therapy consisting of any of the following medications for a&#xD;
             period of at least 30 days prior to the first dose: glucocorticoid, and/or&#xD;
             anti-malarials, and/or immunosuppressive agents.&#xD;
&#xD;
          6. Have a positive test for anti-dsDNA antibody (&gt; normal range) and/or anti-nuclear&#xD;
             antibody (ANA) and/or anti-Smith antibody at screening.&#xD;
&#xD;
          7. Women of childbearing potential must take a complementary barrier method of&#xD;
             contraception in combination with a highly effective method of contraception at&#xD;
             screening, throughout the trial, and within 90 days after the last dose of the&#xD;
             investigational agent. In this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical conditions:&#xD;
&#xD;
          1. Pregnant or lactating women, and men or women who have birth plans in the past 12&#xD;
             months.&#xD;
&#xD;
          2. Have neuropsychiatric systemic lupus erythematosus (NPSLE) within 6 months prior to&#xD;
             the first dose, including seizures, psychosis, organic brain syndrome, cerebrovascular&#xD;
             accident, cranial neuropathy, cerebritis, cerebral vasculitis or lupus headache.&#xD;
&#xD;
          3. Have severe lupus nephritis, or have required hemodialysis or high-dose glucocorticoid&#xD;
             within 90 days prior to the first dose.&#xD;
&#xD;
          4. Have autoimmune diseases other than SLE (excluding secondary Sjogren's syndrome).&#xD;
&#xD;
          5. Have a history of any non-SLE disease that has required treatment with oral or&#xD;
             intravenous or intramuscular or subcutaneous injection glucocorticoids for more than a&#xD;
             total of 2 weeks within the last 24 weeks prior to signing the ICF.&#xD;
&#xD;
          6. Have a history of or current diagnosis of Central Nervous System (CNS) diseases.&#xD;
&#xD;
          7. Have clinically documented cardiovascular diseases that are obviously unstable or not&#xD;
             effectively treated.&#xD;
&#xD;
          8. Have significant active lung diseases (e.g., interstitial lung disease, obstructive&#xD;
             pulmonary disease).&#xD;
&#xD;
          9. Have severe hepatobiliary diseases.&#xD;
&#xD;
         10. Have a history of malignant neoplasm.&#xD;
&#xD;
         11. Have a history of a major organ transplant or hematopoietic stem cell/marrow&#xD;
             transplant.&#xD;
&#xD;
         12. Have known allergies to any component of the investigational agent as described in the&#xD;
             Protocol.&#xD;
&#xD;
             Concomitant medication and surgery:&#xD;
&#xD;
         13. Have received rituximab, epratuzumab, or any other B cell-depleting therapy within 12&#xD;
             months prior to randomization.&#xD;
&#xD;
         14. Have received cyclophosphamide and chlorambucil within 6 months prior to&#xD;
             randomization.&#xD;
&#xD;
         15. Have received belimumab, tumor necrosis factor (TNF) blockers, interleukin receptor&#xD;
             blockers or other biological agents within 3 months prior to randomization (or 5&#xD;
             half-lives, whichever is longer).&#xD;
&#xD;
             Lab tests:&#xD;
&#xD;
         16. Have a positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
         17. Have a positive test for Hepatitis B Surface Antigen (HBsAg) or hepatitis C antibody,&#xD;
             or have a positive test for hepatitis B virus (HBV) DNA by Polymerase Chain Reaction&#xD;
             (PCR) if positive for Hepatitis B Core Antibody (HBcAb).&#xD;
&#xD;
         18. Have abnormal tissue or organ function, meeting any of the following at screening:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1.5 × 10^9/L; hemoglobin &lt; 90 g/L; lymphocyte&#xD;
                  count &lt; 0.8 × 10^9 /L.&#xD;
&#xD;
               -  Calculated estimated glomerular filtration rate (eGFR) using the Chronic Kidney&#xD;
                  Disease Epidemiology Collaboration (CKD-EPI) equation &lt; 45 mL/min/1.73 m2.&#xD;
&#xD;
             Others:&#xD;
&#xD;
         19. Have other conditions that are not appropriate for participation in the trial as&#xD;
             considered by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhanguo Li, PhD</last_name>
    <phone>010-88324172</phone>
    <email>Zgli@yahoo.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhao Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zongwen Shuai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanguo Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GuoChun Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanying Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of XiaMen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guixiu Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niansheng Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Seventh Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518107</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruojie Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guilin Medical University</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <zip>541001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanyou Mo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of HeBei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minghua Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei People's Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>Contact: Junsong Li</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junsong Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Qiqihar</name>
      <address>
        <city>Qiqihar</city>
        <state>Heilongjiang</state>
        <zip>161005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Zhong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaofei Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengyun Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anbin Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second XIANGYA Hospital Of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Tian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yiyang Central Hospital</name>
      <address>
        <city>Yiyang</city>
        <state>Hunan</state>
        <zip>413000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuzhou Central Hospital</name>
      <address>
        <city>Zhuzhou</city>
        <state>Hunan</state>
        <zip>412000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenhua Wen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiujiang NO.1 People's Hospital</name>
      <address>
        <city>Jiujiang</city>
        <state>Jiangxi</state>
        <zip>332000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ju Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rui Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Provincial People's Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of china medical university</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaofei Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Nei Monggol Autonomous Region</state>
        <zip>010000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongbin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Binzhou Medical College</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <zip>256699</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuebin Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jining First People's Hospital</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhong Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi People's Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zunzhong Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheng Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zili Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoxia Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi 'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lan He</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Wei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinjiang Uygur Autonomous Region People's Hospital</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijun Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Huzhou</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <zip>313002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaobing Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Ningbo</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Qin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Wenling</name>
      <address>
        <city>Wenling</city>
        <state>Zhejiang</state>
        <zip>317500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenzhou People's Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suxian Lin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>June 2, 2023</last_update_submitted>
  <last_update_submitted_qc>June 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

